1. Scrip
  2. >>Focus On Asia
  3. >>China

Watch Out Sanofi! Chinese Fast-Follower Emerges With Dupixent Rival

Promising Top-Line Data

 
• By Dexter Jie Yan

Keymed’s anti-IL-4Rα antibody stapokibart has delivered compelling top-line efficacy and safety results in a China Phase III study, which could help it challenge Sanofi/Regeneron’s Dupixent in the country.

fast followers
Keymed's stapokibart is closing in on Dupixent in the atopic dermatitis space in China • Source: Shutterstock

Stapokibart (CM310, a monoclonal antibody against interleukin-4 receptor alpha (IL-4Rα) from China-based biotech Keymed Biosciences Inc. , appears set to emerge as a rival to Sanofi/Regeneron Pharmaceuticals, Inc.’s Dupixent (dupilumab) in the country, backed by positive new top-line Phase III results in adult moderate-to-severe atopic dermatitis.

Key Takeaways

  • Top-line results from a Phase III trial of Keymed’s anti-IL-4Rα antibody stapokibart (CM310) in Chinese adults with moderate-to-severe atopic dermatitis were presented at...

The outcomes from the 500-patient, China-only CM310AD005 trial, which is still ongoing, show an Investigator’s Global Assessment (IGA) score of 0/1 with a reduction of ≥ 2 points at week...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Strong Data For CARsgen’s CAR-T In Late-Line Gastric Cancer

 
• By Dexter Jie Yan

In first confirmatory randomized controlled trial of any CAR-T therapy in solid tumors, CARsgen’s Claudin 18.2-targeting satri-cel reduced risk of death or disease progression by 63% in Chinese patients with gastric/gastroesophageal junction cancer.

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

More from Focus On Asia

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Tech Convergence, Quality Data Needed To Accelerate Korea’s AI-Powered R&D

 
• By Jung Won Shin

AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.

Strong Data For CARsgen’s CAR-T In Late-Line Gastric Cancer

 
• By Dexter Jie Yan

In first confirmatory randomized controlled trial of any CAR-T therapy in solid tumors, CARsgen’s Claudin 18.2-targeting satri-cel reduced risk of death or disease progression by 63% in Chinese patients with gastric/gastroesophageal junction cancer.